

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/809,655
				Filing Date	03/25/2004
				First Named Inventor	Zhonglin Hao
				Art Unit	1653
				Examiner Name	Agnes Rooke
				Attorney Docket Number	00497-09
Sheet	1	of	1		


[illegible][illegible]

Examiner Signature	Agnes B. Rucke	Date Considered	May 4, 2005
--------------------	----------------	-----------------	-------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/809.655
		Filing Date	03/25/2004
		First Named Inventor	Zhonglin HAO
		Group Art Unit	1653
		Examiner Name	Agnès Roche
Sheet 1 of 1	Attorney Docket Number	00497-09	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AR	A	Schellenberger, V., Turck, C. W., Hedstrom, L. and Ritter, W. J. (1993). Mapping the S' Subsites of Serine Proteases Using Acyl Transfer to Mixtures of Peptide Nucleophiles. Biochemistry, Vol. 32, pp. 4349-4353.	

Examiner Signature	Agnès B. Roche	Date Considered	May 4, 2005
--------------------	----------------	-----------------	-------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/809,655</td> </tr> <tr> <td>Filing Date</td> <td>03/25/2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Zhonglin Hao</td> </tr> <tr> <td>Group Art Unit</td> <td>1653</td> </tr> <tr> <td>Examiner Name</td> <td>Agnes Rooke</td> </tr> <tr> <td>Attorney Docket Number</td> <td>00497-09</td> </tr> </table>		Application Number	10/809,655	Filing Date	03/25/2004	First Named Inventor	Zhonglin Hao	Group Art Unit	1653	Examiner Name	Agnes Rooke	Attorney Docket Number	00497-09
Application Number	10/809,655														
Filing Date	03/25/2004														
First Named Inventor	Zhonglin Hao														
Group Art Unit	1653														
Examiner Name	Agnes Rooke														
Attorney Docket Number	00497-09														
Sheet	1	of	2												

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AR	A	Naz, Rajesh K: "Application of Sperm Antigens in Immun contraception", Frontiers in Bioscience 1, e87-95, Sep. 1 (1996).	
	B	O'HERN, PATRICIA A. et al: "Reversible Contraception in Female Baboons Immunized with a Synthetic Epitope of Sperm-Specific Lactate Dehydrogenase", Biology of Reproduction, Vol. 52, pp 331-339, (1995).	
	C	DATABASE EMBL 'Online!', Accession Number AF203447, 12 Nov. 2000, HAO, Z. et al.; "Homo Sapiens sperm acrosome membrane protein SAMP32, mRNA, complete cds".	
	D	DATABASE EMBL 'Online!', Accession Number AW173256, 17 Nov. 1999, NATIONAL CANCER INSTITUTE, CANCER GENOME ANATOMY PROJECT (CGAP): "Homo Sapiens cDNA clone".	
	E	DATABASE EMBL 'Online!', Accession Number AA824354, 20 Feb 1998, NATIONAL CANCER INSTITUTE, CANCER GENOME ANATOMY PROJECT (CGAP): "Homo Sapiens cDNA clone".	
	F	DATABASE EMBL 'Online, Accession No. AA431165, 25 May 1997, HILLIER, L. ET AL.; "zw71g10.r1 Soares_testis_NHT Homo sapiens cDNA clone".	
	G	DATABASE GENESEQ [Online], Accession No. AAV63171, 12 Jan. 1999, AGOSTINO MJ, et al.: "cDNA from clone cf50_1 which encodes a secreted protein".	
	H	DATABASE GENESEQ [ONLINE], Accession No. AAA37094, 8 August 2000, BAKER, K et al.; "Human PRO1418 (UNQ732) cDNA Sequence SEQ ID NO:264".	
	I	DATABASE GENESEQ [ONLINE], Accession No. AAW80397, 12 January 1999, AGOSTINO MJ et al: "A Secreted Protein Encoded by Clone cf50_1".	
	J	DATABASE GENESEQ [ONLINE], Accession No. AAY99412, 8 August 2000, BAKER, K et al, "Human PRO1418 (UNQ732) Amino Acid Sequence SEQ ID NO:265".	
↓	K	CHEN, MICHELLEE S., et al.: "Role of the integrin-associated protein CD9 in binding between sperm ADAM 2 and the egg integrin α6β1: Implications for Murine Fertilization", PNAS, Vol 96, No. 21, pp 11830-11835, Oct 12 (1999).	

Examiner Signature: <u>Agnes B. Rooke</u>	Date Considered: <u>May 4, 2005</u>
---	-------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/809,655</td> </tr> <tr> <td>Filing Date</td> <td>03/25/2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Zhonglin Hao</td> </tr> <tr> <td>Group Art Unit</td> <td>1653</td> </tr> <tr> <td>Examiner Name</td> <td>Agnes Brooke</td> </tr> <tr> <td>Attorney Docket Number</td> <td>00497-09</td> </tr> </table>		Application Number	10/809,655	Filing Date	03/25/2004	First Named Inventor	Zhonglin Hao	Group Art Unit	1653	Examiner Name	Agnes Brooke	Attorney Docket Number	00497-09
Application Number	10/809,655														
Filing Date	03/25/2004														
First Named Inventor	Zhonglin Hao														
Group Art Unit	1653														
Examiner Name	Agnes Brooke														
Attorney Docket Number	00497-09														
Sheet	2	of	2												

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AR	L	LE NOIR, FRANCOIS, et al.: "Severely Reduced Female Fertility in CD9-Deficient Mice", SCIENCE, Vol. 287, Jan. 14 (2000).	
↓	M	DIEKMAN, ALAN B. et al.: "N-linked glycan of a sperm CD52 glycoform associated with human infertility", FASEB, Vol. 13, pp 1303-1308, Aug. (1999).	
↓	N	MIYADO, Kenji, et al.: "Requirement of CD9 on the Egg Plasma Membrane for Fertilization", SCIENCE, Vol 287, Jan 14, (2000).	

Examiner Signature	Agnes B. Brooke	Date Considered	May 4, 2005
--------------------	-----------------	-----------------	-------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.